ID   KTCTL-13
AC   CVCL_5870
SY   KTCTL13; KTCTL 13; RCC-ER; RCCER
DR   ArrayExpress; E-MTAB-3610
DR   cancercelllines; CVCL_5870
DR   Cell_Model_Passport; SIDM00820
DR   CLS; 300238
DR   Cosmic; 972923
DR   Cosmic; 1352060
DR   Cosmic; 1751971
DR   Cosmic-CLP; 1524417
DR   DepMap; ACH-002188
DR   EGA; EGAS00001000978
DR   GDSC; 1524417
DR   GEO; GSM1670361
DR   PharmacoDB; RCCER_1288_2019
DR   PRIDE; PXD030304
DR   Wikidata; Q54900630
RX   PubMed=7915601;
RX   PubMed=8086765;
RX   PubMed=11929824;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=28489074;
RX   PubMed=30894373;
RX   PubMed=35839778;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Asp143Glufs*16 (c.429del); Zygosity=Unspecified (PubMed=7915601).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.27%; Native American=0.52%; East Asian, North=1.51%; East Asian, South=0%; South Asian=1.01%; European, North=76.23%; European, South=20.46% (PubMed=30894373).
CC   Misspelling: KTCL13; Cosmic=972923; PubMed=7915601.
CC   Derived from site: In situ; Kidney; UBERON=UBERON_0002113.
ST   Source(s): CLS; Cosmic-CLP
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 11,13
ST   D16S539: 9,12
ST   D18S51: 14,17
ST   D19S433: 13.2,15.2
ST   D21S11: 30,31.2
ST   D2S1338: 17,23
ST   D3S1358: 18
ST   D5S818: 11
ST   D7S820: 10,12
ST   D8S1179: 12,15
ST   FGA: 21,26
ST   Penta D: 10,12
ST   Penta E: 11,12
ST   TH01: 6
ST   TPOX: 8,11
ST   vWA: 17,18
DI   NCIt; C4033; Clear cell renal cell carcinoma
DI   ORDO; Orphanet_319276; Clear cell renal carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   57Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 30
//
RX   PubMed=7915601; DOI=10.1038/ng0594-85;
RA   Gnarra J.R., Tory K., Weng Y., Schmidt L.S., Wei M.H., Li H., Latif F.,
RA   Liu S., Chen F., Duh F.-M., Lubensky I.A., Duan D.R., Florence C.,
RA   Pozzatti R., Walther M.M., Bander N.H., Grossman H.B., Brauch H.,
RA   Pomer S., Brooks J.D., Isaacs W.B., Lerman M.I., Zbar B.,
RA   Linehan W.M.;
RT   "Mutations of the VHL tumour suppressor gene in renal carcinoma.";
RL   Nat. Genet. 7:85-90(1994).
//
RX   PubMed=8086765; DOI=10.1007/BF00252823;
RA   Gross A.J., Wolff M., Fandrey J., Miersch W.-D., Dieckmann K.-P.,
RA   Jelkmann W.;
RT   "Prevalence of paraneoplastic erythropoietin production by renal cell
RT   carcinomas.";
RL   Clin. Investig. 72:337-340(1994).
//
RX   PubMed=11929824;
RA   Batrla R., Linnebacher M., Rudy W., Stumm S., Wallwiener D.,
RA   Guckel B.;
RT   "CD40-expressing carcinoma cells induce down-regulation of CD40 ligand
RT   (CD154) and impair T-cell functions.";
RL   Cancer Res. 62:2052-2057(2002).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=28489074; DOI=10.1038/ncomms15165;
RA   Sinha R., Winer A.G., Chevinsky M., Jakubowski C., Chen Y.-B., Dong Y.-Y.,
RA   Tickoo S.K., Reuter V.E., Russo P., Coleman J.A., Sander C.,
RA   Hsieh J.J.-D., Hakimi A.A.;
RT   "Analysis of renal cancer cell lines from two major resources enables
RT   genomics-guided cell line selection.";
RL   Nat. Commun. 8:15165.1-15165.10(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//